Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
26 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
8-K
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
28 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
31 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Other Events
5 Dec 23
8-K
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
17 Nov 23
8-K
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
9 Nov 23
8-K/A
Submission of Matters to a Vote of Security Holders
2 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
8 Aug 23
424B5
Prospectus supplement for primary offering
8 Aug 23
S-3ASR
Automatic shelf registration
28 Feb 23
S-8
Registration of securities for employees
19 Jan 23
424B5
Prospectus supplement for primary offering
19 Dec 22
FWP
Free writing prospectus
15 Dec 22
424B5
Prospectus supplement for primary offering
14 Dec 22
S-8
Registration of securities for employees
8 Aug 22
S-8
Registration of securities for employees
5 Aug 21
424B5
Prospectus supplement for primary offering
15 Jun 21
Proxies
DEFA14A
Additional proxy soliciting materials
7 Jul 23
DEFA14A
Additional proxy soliciting materials
29 Jun 23
DEFA14A
Additional proxy soliciting materials
20 Jun 23
DEFA14A
Additional proxy soliciting materials
15 Jun 23
DEFR14A
Revised proxy
3 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
3 May 22
DEF 14A
Definitive proxy
2 May 22
Other
EFFECT
Notice of effectiveness
10 Jan 20
CORRESP
Correspondence with SEC
7 Jan 20
UPLOAD
Letter from SEC
6 Jan 20
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
12 Jun 18
EFFECT
Notice of effectiveness
12 Jan 18
CORRESP
Correspondence with SEC
10 Jan 18
UPLOAD
Letter from SEC
9 Jan 18
UPLOAD
Letter from SEC
21 Dec 17
CORRESP
Correspondence with SEC
4 Dec 17
Ownership
SC 13D/A
SHAH CAPITAL MANAGEMENT
15 Apr 24
SC 13D
SHAH CAPITAL MANAGEMENT
15 Apr 24
4
John Trizzino
26 Mar 24
4
Elaine O'Hara
26 Mar 24
4
James Patrick Kelly
26 Mar 24
4
Filip Dubovsky
26 Mar 24
4
Mark J Casey
26 Mar 24
4
John C Jacobs
26 Mar 24
4
James Patrick Kelly
12 Mar 24
4
Filip Dubovsky
12 Mar 24